Company Overview - Baihua Medicine has seen a stock price increase of 52.05% year-to-date, with a recent 0.10% rise over the last five trading days, 16.24% over the last 20 days, and 40.93% over the last 60 days [2] - The company has appeared on the stock market's "Dragon and Tiger List" four times this year, with the most recent appearance on September 4, where it recorded a net buy of -57.5752 million yuan [2] - Baihua Medicine's main business includes early drug discovery, drug CMC development, clinical trials, registration applications, and various pharmaceutical services [2] Financial Performance - As of June 30, the number of shareholders for Baihua Medicine was 30,000, a decrease of 26.42% from the previous period, while the average circulating shares per person increased by 35.95% to 12,799 shares [3] - For the first half of 2025, Baihua Medicine reported revenue of 202 million yuan, a year-on-year increase of 2.95%, and a net profit attributable to shareholders of 25.4834 million yuan, up 12.45% year-on-year [3] Revenue Composition - The revenue composition of Baihua Medicine is as follows: clinical trials account for 49.39%, pharmaceutical research and consistency evaluation for 42.67%, leasing and property services for 6.69%, and other income for 0.94% [2] Market Activity - On September 18, Baihua Medicine's stock price fell by 2.05% to 10.02 yuan per share, with a trading volume of 278 million yuan and a turnover rate of 7.07% [1] - The net inflow of main funds was 4.0879 million yuan, with large orders accounting for 19.69% of purchases and 18.16% of sales [1]

Core Viewpoint - Shuyou Shen's stock price has shown significant volatility, with a year-to-date increase of 409.18%, but recent declines in the short term raise questions about future performance [1][2]. Company Overview - Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. was established on August 16, 2002, and listed on April 15, 2011. The company primarily engages in the research, production, and sales of biological products and some chemical drugs [1]. - The main revenue sources are: 59.17% from injectable mouse nerve growth factor (Sutai), 33.19% from compound polyethylene glycol electrolyte powder, and 7.63% from other products [1]. Financial Performance - For the first half of 2025, Shuyou Shen reported revenue of 126 million yuan, a year-on-year decrease of 31.14%, and a net profit attributable to shareholders of -24.64 million yuan, a decline of 619.70% [2]. - The company has distributed a total of 771 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 29.20% to 31,700, with an average of 14,327 shares held per shareholder, a decrease of 22.60% [2]. - New institutional shareholders include several funds, with notable holdings such as 15.72 million shares by Xingquan Helun Mixed A and 8.81 million shares by Xingquan Commercial Model Mixed A [3]. Market Activity - On September 18, the stock price rose by 2.00% to 37.73 yuan per share, with a trading volume of 521 million yuan and a turnover rate of 3.09%. The total market capitalization reached 18.026 billion yuan [1]. - The stock has appeared on the daily trading leaderboard seven times this year, with the most recent occurrence on June 9, where it recorded a net buy of -54.65 million yuan [1].

专题：北京公募基金高质量发展系列活动 新时代、新基金、新价值 作者：经雷 嘉实基金总经理 公募基金通过深度的基本面研究，发挥其价值发现、价值创造、风险管理等专业投资能力，将社会资本 高效配置到国家战略指引、最具发展潜力的产业领域，如科技创新、先进制造、绿色能源等，助力现代 化产业体系建设。以嘉实为例，截至2025年上半年，嘉实基金持有的各类股票总市值接近4000亿元，其 中配置比例居前的细分行业包括电子、有色金属、计算机、通信等新质生产力领域。 深度研究不仅需涵盖个股与行业，更需对产业趋势、宏观经济持续追踪和认知判断。近年来，嘉实基金 就前瞻性关注并加大了对半导体、人工智能、生物医药等战略新兴行业的配置力度，通过主被动权益产 品的打造让投资者有便捷普惠的途径参与到这些战略新兴产业投资机会的捕捉中。 发现产业价值，终极落脚点是让投资者有收获。包括嘉实基金在内的公募基金公司，着力通过构建系统 化的深度研究与投资体系等，力争让投资者在产业升级中共享投资回报。今年上半年，嘉实基金旗下公 募基金创造投资回报约210亿元。其中，围绕新质生产力布局的产品也到了投资者的认可和积极参与。 根据统计，截止今年上半年，这些分别聚焦 ...

Core Insights - The AH premium level has become a key indicator for foreign capital allocation direction, with over 50 A-share companies applying for secondary listings in Hong Kong since 2025, highlighting the increasing value of dual-listed stocks [1] - Foreign investors show a clear preference for low-premium stocks, with smaller-cap stocks having an average AH premium rate exceeding 95%, while larger-cap stocks have much lower rates of 4% (A-shares) and 17% (H-shares) [1] - Historical data indicates a correlation of 0.56 between the AH premium index's fluctuations and the scale difference of foreign inflows into H-shares and A-shares since 2020, suggesting that a rebound in the premium rate may lead to increased foreign investment in H-shares [1] - The AH premium index has declined from a high of 157 in February last year to a new low of 123 in August 2025, indicating potential for foreign capital to return to Hong Kong stocks if the premium rate reverts to the mean [1] - The Hong Kong stock market is showing significant investment value due to a "triple resonance" of policy dividends, technological innovation breakthroughs, and continuous liquidity improvement [1] - Hong Kong is home to leading technology companies in AI, biomedicine, and new energy vehicles, which possess core competitiveness in cutting-edge fields [1] - With the onset of the Federal Reserve's interest rate cuts and continuous inflow of southbound capital, Hong Kong stocks may experience dual opportunities for performance enhancement and value reassessment [1] Related ETFs - AI Full Industry Chain - Hong Kong Stock Connect Technology ETF (159101) [2] - New Consumption Forces - Hang Seng Consumption ETF (513230) [2] - Pure Internet - Hang Seng Internet ETF (513330) [2] - Focus on Innovative Drugs - Hang Seng Pharmaceutical ETF (159892) [2]

Core Viewpoint - Chenxin Pharmaceutical has shown significant stock performance with a year-to-date increase of 60.13%, despite a recent decline over the past 20 days [1][2]. Group 1: Stock Performance - On September 18, Chenxin Pharmaceutical's stock rose by 2.07%, reaching 21.65 CNY per share, with a trading volume of 1.59 billion CNY and a turnover rate of 1.64%, resulting in a total market capitalization of 9.802 billion CNY [1]. - The stock has experienced a 1.26% increase over the last five trading days, a 27.83% decrease over the last 20 days, and a 56.32% increase over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" four times this year, with the most recent appearance on September 3, where it recorded a net purchase of 51.8339 million CNY [1]. Group 2: Financial Performance - For the first half of 2025, Chenxin Pharmaceutical reported a revenue of 1.740 billion CNY, a year-on-year decrease of 15.97%, and a net profit attributable to shareholders of 229 million CNY, down 15.23% year-on-year [2]. - The company has distributed a total of 1.112 billion CNY in dividends since its A-share listing, with 548 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for Chenxin Pharmaceutical was 35,900, an increase of 68.07% from the previous period, with an average of 12,602 shares held per shareholder, a decrease of 40.50% [2]. - Hong Kong Central Clearing Limited is the seventh-largest circulating shareholder, holding 6.9075 million shares, an increase of 1.9689 million shares from the previous period [3].

Core Viewpoint - Baiotai's stock price has shown significant fluctuations in 2023, with a year-to-date increase of 61.92% and a recent decline over the past 20 days [1][2]. Group 1: Stock Performance - As of September 18, Baiotai's stock price rose by 2.02% to 31.38 CNY per share, with a total market capitalization of 12.994 billion CNY [1]. - The stock has experienced a 1.16% increase over the last five trading days, a 5.74% decrease over the last 20 days, and a 27.41% increase over the last 60 days [1]. Group 2: Financial Performance - For the first half of 2025, Baiotai reported a revenue of 442 million CNY, reflecting a year-on-year growth of 9.84% [2]. - The company recorded a net profit attributable to shareholders of -125 million CNY, which is a 47.25% improvement compared to the previous year [2]. Group 3: Company Overview - Baiotai Biopharmaceutical Co., Ltd. was established on July 28, 2003, and went public on February 21, 2020 [1]. - The company's main business activities include the research and production of innovative drugs and biosimilars, with 91.90% of revenue coming from drug sales [1].

Group 1 - The core viewpoint of the news is that Xintai has shown significant stock performance with a year-to-date increase of 76.40%, despite a slight decline in the last five trading days [1] - As of June 30, 2025, Xintai achieved a revenue of 2.131 billion yuan, representing a year-on-year growth of 4.32%, and a net profit of 365 million yuan, with a growth of 6.10% [2] - The company has a diverse revenue structure, with 81.69% from formulations, 8.54% from medical devices, 7.17% from raw materials, and 2.59% from other sources [1] Group 2 - Xintai has distributed a total of 7.204 billion yuan in dividends since its A-share listing, with 1.649 billion yuan distributed in the last three years [3] - As of June 30, 2025, the number of shareholders decreased by 0.79% to 24,000, while the average circulating shares per person increased by 0.80% to 46,403 shares [2] - The top ten circulating shareholders include notable funds, with China Europe Medical Health Mixed A increasing its holdings by 12.0972 million shares [3]

Core Points - The stock price of Junshi Biosciences has increased by 70.44% year-to-date, with a recent decline of 2.41% over the last five trading days [2] - The company reported a revenue of 1.168 billion yuan for the first half of 2025, representing a year-on-year growth of 48.64%, while the net profit attributable to shareholders was -413 million yuan, a year-on-year increase of 36.01% [2] Company Overview - Junshi Biosciences, established on December 27, 2012, is located in Shanghai and specializes in the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs [2] - The main revenue sources for the company are drug sales (90.67%), technology licensing and royalties (8.74%), and technical services and others (0.59%) [2] Stock Performance and Market Activity - As of September 18, the stock price was 46.58 yuan per share, with a market capitalization of 47.823 billion yuan [1] - The trading volume on September 18 was 151 million yuan, with a turnover rate of 0.43% [1] - Institutional holdings show that the top ten circulating shareholders include various ETFs, with notable changes in shareholding [3]

- CVINFO TIN 投中信息 CVINFO www.chinaventure.com.cn 投中统计: 8月VC/PE市场环比小幅回落 募投数量同比增加超两成~"> 投中研究院 2025.09 BUSINESS STRATEGY Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut 由 数 投中数据 1 01 / ∞♥CPE市场募资分析 8月基金数量520支，环比减少9%，同比增加 O 投 中 数 据 24%。 浙鲁苏新设基金再领跑，嘉兴、青岛地区最活跃。 O Urce 投中数据 本月重点新设募集案例 O SOUrce 投 中 数 据 本月重点完成募集案例 ○ 投中数据 投中数据 기 JICE 投中数据 投中数据 OUTC 投 中 数 据 Copyright © 投中信息 ISOUTC www.cvinfo.com.cn 30 CVINH YNY CVINFO 2 Copyright © 投中信息 www. ...

Group 1 - The core viewpoint of the news is that Tibet Pharmaceutical's stock has experienced fluctuations, with a recent decline of 2.07% and a year-to-date increase of 48.54% [1] - As of September 17, the stock price is 52.09 yuan per share, with a total market capitalization of 16.79 billion yuan [1] - The company has seen a net outflow of main funds amounting to 58.76 million yuan, with significant selling pressure observed [1] Group 2 - For the first half of 2025, Tibet Pharmaceutical reported a revenue of 1.651 billion yuan, reflecting a year-on-year growth of 2.23%, while the net profit attributable to shareholders decreased by 8.96% to 567 million yuan [2] - The company has distributed a total of 2.258 billion yuan in dividends since its A-share listing, with 1.580 billion yuan distributed over the past three years [3] - As of June 30, 2025, the number of shareholders decreased by 8.08% to 45,200, while the average circulating shares per person increased by 8.79% to 7,132 shares [2]